BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25411416)

  • 21. Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma.
    Tsirigotis P; Dray L; Resnick IB; Ackerstein A; Gesundheit B; Elad S; Or R; Shapira MY
    Ann Hematol; 2010 Mar; 89(3):263-72. PubMed ID: 19693502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.
    Kim YR; Kim SJ; Cheong JW; Yang DH; Lee H; Eom HS; Sung YO; Kim HJ; Kang HJ; Lee WS; Park Y; Yang WI; Min YH; Kim JS
    Ann Hematol; 2016 Sep; 95(9):1491-501. PubMed ID: 27324387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.
    Armand P; Welch S; Kim HT; LaCasce AS; Jacobsen ED; Davids MS; Jacobson C; Fisher DC; Brown JR; Coughlin E; Freedman AS; Chen YB
    Br J Haematol; 2013 Mar; 160(5):608-17. PubMed ID: 23278720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome.
    Noring K; Carlsten M; Sonnevi K; Wahlin BE
    BMC Cancer; 2021 May; 21(1):500. PubMed ID: 33947353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
    Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
    Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma.
    Frosch Z; Luskin MR; Landsburg DJ; Schuster SJ; Svoboda J; Loren AW; Porter DL; Stadtmauer EA; Nasta SD
    Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):92-7. PubMed ID: 25174772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study.
    Chin CK; Lim KJ; Lewis K; Jain P; Qing Y; Feng L; Cheah CY; Seymour JF; Ritchie D; Burbury K; Tam CS; Fowler NH; Fayad LE; Westin JR; Neelapu SS; Hagemeister FB; Samaniego F; Flowers CR; Nastoupil LJ; Dickinson MJ
    Br J Haematol; 2020 Dec; 191(5):806-815. PubMed ID: 33065767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma.
    Bonm AV; Gibson AW; Holmberg LA; Mielcarek M; McGranahan T; Taylor LP; Graber JJ
    J Neurooncol; 2021 Jan; 151(2):193-200. PubMed ID: 33398532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
    Alkhaldi H; Reinhardt A; Barnett M; Kundu S; Hosing C; Ramdial J; Saini N; Srour S; Alousi A; Kebriaei P; Popat U; Qazilbash M; Champlin R; Shpall EJ; Gulbis A; Shigle TL; Dabaja B; Pinnix C; Ahmed S; Steiner R; Andersson BS; Nieto Y
    Transplant Cell Ther; 2023 Nov; 29(11):690-694. PubMed ID: 37607645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experience.
    Tedjaseputra A; Gilbertson M; Low M; Fedele PL; Kumar B; Simpson I; Grigoriadis G; Shortt J; Opat S; Gregory GP
    Intern Med J; 2021 Nov; 51(11):1825-1834. PubMed ID: 32609419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.
    Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA
    Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
    Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
    Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
    William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
    Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
    Olivieri J; Mosna F; Pelosini M; Fama A; Rattotti S; Giannoccaro M; Carli G; Tisi MC; Ferrero S; Sgherza N; Mazzone AM; Marino D; Calimeri T; Loseto G; Saraceni F; Tomei G; Sica S; Perali G; Codeluppi K; Billio A; Olivieri A; Orciuolo E; Matera R; Stefani PM; Borghero C; Ghione P; Cascavilla N; Lanza F; Chiusolo P; Finotto S; Federici I; Gherlinzoni F; Centurioni R; Fanin R; Zaja F;
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1814-1822. PubMed ID: 29857196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
    Ciochetto C; Botto B; Passera R; Bellò M; Benevolo G; Boccomini C; Castellino A; Chiappella A; Freilone R; Nicolosi M; Orsucci L; Pecoraro C; Pregno P; Bisi G; Vitolo U
    Ann Hematol; 2018 Sep; 97(9):1619-1626. PubMed ID: 29663029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12.
    Baetz T; Chen BE; Couban S; Tom Kouroukis C; Buckstein R; Kuruvilla J; Howson-Jan K; Szwajcer D; Federico M; Meyer RM; Djurfeldt MS; Hay AE; Shepherd L; Crump M
    Leuk Lymphoma; 2017 Jan; 58(1):64-69. PubMed ID: 27266754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.
    Rancea M; Monsef I; von Tresckow B; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2013 Jun; (6):CD009411. PubMed ID: 23784872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.